Cultured Growth: CT’s economic, cultural siren song attracts Israeli firms Article by: GREGORY SEAY, Photograph by STEVE LASCHEVER Connecticut’s coordinated recruiting efforts to lure more international firms to the state are resonating loudest among nascent technology firms in Israel, observers say. At least two Israeli technology firms have opened doors in this state in recent years, and dozens more are exploring opportunities to lease or buy real estate and employ workers to ply the broader U.S. market with their products and services. One, Biological Industries, last fall opened in Cromwell, where it stores and distributes cultures used to grow...Read More
Author: Biological Industries
As part of our ongoing efforts to bring you added value in terms of innovation, quality and regulatory aspects, Biological Industries (BI) announces acceptance by the FDA of a Drug Master File (DMF) for our MSC NutriStem® XF Basal Medium and Supplement. BI’s defined, xeno-free, serum-free medium, designed to support the isolation and growth of human mesenchymal stem cells. MSC NutriStem® XF is considered in regulatory aspects as an “Ancillary Material” meaning; a material used in the process but is not part of the final product. The USP defines the requirements of ancillary materials in a general monograph USP<1043> “Ancillary Materials for Cell-,Gene-, and Tissue-Engineered Products”. In accordance to the USP Risk classification (4 tiers), the product is characterized as low- risk. Drug Master Files are confidential documents submitted to the FDA which outline, in detail, manufacturing and procedural details for drugs or biological materials used in animals or humans. In order to reference information regarding MSC NutriStem® in DMF number 29469, please contact us by filling out the following authorization request in accordance with the instruction in the document Requesting Letter of Authorization...Read More
Biological Industries to Present Culture System for Clinical Grade Human Mesenchymal Stem Cells At Research Meeting in Stockholm
KIBBUTZ BEIT HAEMEK, Israel , June 2015 – A serum-free, xeno-free, culture system for the expansion and differentiation of clinical grade human mesenchymal stem cells will be demonstrated by Biological Industries in an ‘innovation showcase’ at an International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden, from June 24-27. Biological Industries VP for Scientific Affairs, David Fiorentini, who will present the showcase, said: “This is an innovative technology which providrd the ability to efficiently differentiate hMSC from various sources into adipocytes, chondrocytes and osteoblasts.” Human mesenchymal stem cells (hMSCs) are multipotent adult stem cells that can...Read More
Join our mailing list to receive the latest news and updates from our team.